Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: purified talc; amaranth aluminium lake; titanium dioxide; stearic acid; magnesium stearate; macrogol 6000; indigo carmine aluminium lake; polyvinyl acetate phthalate; calcium silicate; diethyl phthalate; povidone; hypromellose; citric acid monohydrate; hyprolose - epilepsy: primary generaliszed epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: purified talc; magnesium stearate; titanium dioxide; stearic acid; indigo carmine aluminium lake; calcium silicate; polyvinyl acetate phthalate; hypromellose; citric acid monohydrate; diethyl phthalate; hyprolose; amaranth aluminium lake; povidone; macrogol 6000 - epilepsy: primary generalised epilepsies (petit mal absences, various forms of myoclonic epilepsies and tonic-clonic grand mal seizures). partial (focal) epilepsies either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 400 mg - injection, powder for - excipient ingredients: - epilim iv is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 0.24 mg/g (equivalent: betamethasone, qty 0.2 mg/g) - cream - excipient ingredients: cetomacrogol 1000; cetostearyl alcohol; white soft paraffin; liquid paraffin; purified water; chlorocresol; monobasic sodium phosphate; phosphoric acid; sodium hydroxide - indications as at 23 april 2004 : eczema includiing: atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.

Μάλτα - Αγγλικά - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - magnesium trisilicate, aluminium hydroxide - chewable tablet - magnesium trisilicate 500 mg aluminium hydroxide 250 mg - drugs for acid related disorders

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - sodium valproate -

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - sodium valproate -

Μάλτα - Αγγλικά - Medicines Authority

simru global holdings limited the black church, st. mary’s place, dublin 7, d07 p4ax , ireland - dimethicone, activated, aluminium hydroxide, magnesium hydroxide - oral suspension - dimethicone, activated 25 mg aluminium hydroxide 220 mg magnesium hydroxide 200 mg - drugs for functional gastrointestinal disorders

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

life biopharma sdn. bhd. - amoxicillin trihydrate -

Νότια Αφρική - Αγγλικά - South African Health Products Regulatory Authority (SAHPRA)

cipla -